Literature DB >> 31555680

Preoperative D-dimer level is an independent prognostic factor for non-small cell lung cancer after surgical resection: a systematic review and meta-analysis.

Han-Yu Deng1, Xi Zheng1, Rui Jiang1, Rui-Lan Wang1, Jie Zhou1, Xiao-Ming Qiu1.   

Abstract

BACKGROUND: Whether high preoperative D-dimer level has any impact on long-term survival of patients with surgically treated non-small cell lung cancer (NSCLC) remains unclear. Therefore, we conducted the first meta-analysis focusing specifically on prognostic value of high preoperative D-dimer level in NSCLC patients after surgical resection comprehensively.
METHODS: We conducted a systematic search for relevant studies in PubMed, Embase, and Web of Science on January 28, 2019. Data for analysis consisted of hazard ratio (HR) with 95% confidence interval (CI) of overall survival (OS) and disease-free survival (DFS) from multivariate analysis and were analyzed by using the STATA 12.0 package.
RESULTS: Finally, we included a total of 6 cohort studies consisting of 1,817 patients with surgically treated NSCLC for analysis. Our meta-analysis found that NSCLC patients with high preoperative D-dimer level had a significantly worse OS (random effects: HR =2.04; 95% CI: 1.30-3.20; P=0.002; I2=67.4%) and DFS (fixed effects: HR =1.98; 95% CI: 1.41-2.78; P<0.001; I2=0.0%) than these with normal preoperative D-dimer level after surgery. However, potential heterogeneity and publication bias was observed during analysis.
CONCLUSIONS: High pretreatment level of D-dimer remains to be an independent predictor of poor prognosis in NSCLC patients after surgery. Further well-conducted studies with appropriate adjustments are needed to confirm and update our conclusions.

Entities:  

Keywords:  D-dimer; meta-analysis; non-small cell lung cancer (NSCLC); prognosis; surgery

Year:  2019        PMID: 31555680      PMCID: PMC6736809          DOI: 10.21037/atm.2019.05.35

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  33 in total

Review 1.  Non-small-cell lung cancer.

Authors:  Peter Goldstraw; David Ball; James R Jett; Thierry Le Chevalier; Eric Lim; Andrew G Nicholson; Frances A Shepherd
Journal:  Lancet       Date:  2011-05-10       Impact factor: 79.321

Review 2.  Coagulation and cancer: biological and clinical aspects.

Authors:  A Falanga; M Marchetti; A Vignoli
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

Review 3.  Treatment of lung cancer.

Authors:  Shirish M Gadgeel; Suresh S Ramalingam; Gregory P Kalemkerian
Journal:  Radiol Clin North Am       Date:  2012-09       Impact factor: 2.303

4.  Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.

Authors:  Dimosthenis Antoniou; Georgia Pavlakou; George P Stathopoulos; Ioannis Karydis; Evangelia Chondrou; Chrysovalantis Papageorgiou; Fotini Dariotaki; Dimitra Chaimala; Marinos Veslemes
Journal:  Lung Cancer       Date:  2006-08       Impact factor: 5.705

Review 5.  D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism.

Authors:  B H Mavromatis; C M Kessler
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

Review 6.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

Review 7.  Procoagulant mechanisms in tumour cells.

Authors:  Anna Falanga; Marina Panova-Noeva; Laura Russo
Journal:  Best Pract Res Clin Haematol       Date:  2009-03       Impact factor: 3.020

Review 8.  An overview of coagulation disorders in cancer patients.

Authors:  Slavica Kvolik; Marko Jukic; Marko Matijevic; Ksenija Marjanovic; Ljubica Glavas-Obrovac
Journal:  Surg Oncol       Date:  2009-04-25       Impact factor: 3.279

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

10.  Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.

Authors:  Anna Falanga; Alfonso Vignoli; Erika Diani; Marina Marchetti
Journal:  Patient Relat Outcome Meas       Date:  2011-11-23
View more
  5 in total

1.  Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer.

Authors:  Chong Chen; Jianhua Li; Jing Li; Xu Wang; Xiaoyan Wang; Na Du; Li Ren
Journal:  Ann Transl Med       Date:  2020-09

2.  Diagnostic Value of Serum D-Dimer for Detection of Gallbladder Carcinoma.

Authors:  Weihao Kong; Li Zhang; Ran An; Mingwei Yang; Hao Wang
Journal:  Cancer Manag Res       Date:  2021-03-17       Impact factor: 3.989

3.  Incidence of venous thromboembolism and hemorrhage in Chinese patients after pulmonary lobectomy: mechanical prophylaxis or mechanical prophylaxis combined with pharmacological prophylaxis: a randomized controlled trial.

Authors:  Yun Hong; Yanfang Zhang; Yangwei Xiang; Ziqi Ye; Xiaoyang Lu
Journal:  Ann Transl Med       Date:  2021-09

4.  A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer.

Authors:  Hao Shen; Shusheng Wu; Rixin Su; Yaolin Chen; Yifu He
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Dynamics of D-dimer in non-small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism.

Authors:  Lihui Ke; Songping Cui; Shuo Chen; Bin Hu; Hui Li
Journal:  Thorac Cancer       Date:  2020-07-13       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.